Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2005 Nov;106(5 Pt 1):940-5.
doi: 10.1097/01.AOG.0000180394.08406.15.

Postmenopausal hormone therapy: does it cause incontinence?

Jody E Steinauer  1 , L Elaine Waetjen, Eric Vittinghoff, Leslee L Subak, Stephen B Hulley, Deborah Grady, Feng Lin, Jeanette S Brown
Affiliations
Randomized Controlled Trial

Postmenopausal hormone therapy: does it cause incontinence?

Jody E Steinauer et al. Obstet Gynecol. 2005 Nov.

Abstract

Objective: To estimate the effect of hormone therapy on risk of stress and urge urinary incontinence.

Methods: The Heart Estrogen/progestin Replacement Study was a randomized, placebo-controlled, double-blinded trial to evaluate daily oral conjugated estrogen (0.625 mg) plus medroxyprogesterone acetate (2.5 mg) therapy for the prevention of heart disease events in women with established heart disease. The 1,208 participants in Heart Estrogen/progestin Replacement Study who reported no loss of urine in the previous 7 days at baseline are included in this analysis.

Results: During 4.2 years of treatment, 64% of women randomly assigned to hormone therapy compared with 49% of those assigned to placebo reported weekly incontinence (P < .001). The higher risk of incontinence in the hormone group was evident at 4 months, persisted throughout the treatment period, and was independent of the age of the women. The odds ratios for weekly incontinence among women on hormone therapy compared with placebo were 1.5 for urge incontinence (95% confidence interval [CI] 1.2-1.8; P < .001) and 1.7 for stress incontinence (95% CI 1.5-2.1; P < .001). Four years of treatment with hormone therapy caused an excess risk of 12% for weekly urge incontinence and 16% for weekly stress incontinence; the corresponding numbers needed to harm were 8.6 (95% CI 5.8-16.6) and 6.2 (95% CI 4.6-9.4).

Conclusion: Estrogen plus progestin therapy increases risk of urge and stress incontinence within 4 months of beginning treatment.

Level of evidence: I.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Cumulative percentage of women reporting incident weekly urinary incontinence at each visit.
See this image and copyright information in PMC

Comment in

References

    1. Hannestad YS, Rortveit G, Sandvik H, Hunskaar S. Norwegian EPINCONT study. Epidemiology of Incontinence in the County of Nord-Trondelag. A community-based epidemiological survey of female urinary incontinence: the Norwegian EPINCONT study. Epidemiology of Incontinence in the County of Nord-Trondelag. J Clin Epidemiol. 2000;53:1150–1157. - PubMed
    1. Jarmy-Di Bella ZI, Girao MJ, Sartori MF, Di Bella Junior V, Lederman HM, Baracat EC, et al. Power Doppler of the urethra in continent or incontinent, pre- and postmenopausal women. Int Urogynecol J Pelvic Floor Dysfunct. 2000;11:148–154. - PubMed
    1. Girao MJ, Jarmy-Di Bella ZI, Sartori MG, Baracat EC, Lima GR. Doppler velocimetry parameters of periurethral vessels in postmenopausal incontinent women receiving estrogen replacement. Int Urogynecol J Pelvic Floor Dysfunct. 2001;12:241–246. - PubMed
    1. Beisland HO, Fossberg E, Moer A, Sander S. Urethral sphincteric insufficiency in postmenopausal females: treatment with phenylpropanolamine and estriol separately and in combination. A urodynamic and clinical evaluation. Urol Int. 1984;39:211–6. - PubMed
    1. Ek A, Andersson KE, Gullberg B, Ulmsten U. Effects of oestradiol and combined norephedrin and oestradiol treatment on female stress incontinence. Zentralbl Gynakol. 1980;102:839–44. - PubMed

Publication types

MeSH terms

Substances